Previous 10 | Next 10 |
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for EU protocol assistance, marketing authorization applications, inspections befo...
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology,...
2024-02-05 16:01:56 ET More on Immix Biopharma, Inc. Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status FDA okays US clinical testing for Immix drug NXC-201 Read the full article on Seeking Alpha For further details see: Immix Biopharma l...
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an under...
2024-01-25 10:00:05 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
2024-01-23 12:48:13 ET Gainers: Rail Vision Ltd ( RVSN ) +274% . FaZe Holdings ( FAZE ) +100% . Nuvve Holding Corp NVVE +50% . Ensysce Biosciences ENSC +48% . Turnstone Biologics Corp ( TSBX ) +41% . Rumble ( RUM ) +38% . ...
LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Adv...
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine , 2019 Dr. Radic is a recognized thought leader in autoimmune CAR-T cell therapy, antibody-mediated disorders and designing CAR-T studies ...
2023-12-18 08:17:02 ET Getaround ( GETR ) +85% . Battalion Oil Corp ( BATL ) +82% . Verrica Pharmaceuticals ( VRCA ) +62% . Cardio Diagnostics Holdings ( CDIO ) +45% . Brilliant Acquisition ( BRLI ) +45% . Northann ( ...
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...